EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

The pivotal role of β‐lactone stereochemistry in the development of SARS ‐ CoV ‐2 M pro inhibitors

Katarzyna Świderek iD, Vicent Moliner iD

Protein Science · 2026-07 · 35 (7)

DOI: 10.1002/pro.70680 ↗

At a glance

Journal article in Protein Science, published online on 2026-06-18. Written by Katarzyna Świderek and 1 co-authors. Institution: BioComp Group, Institute of Advanced Materials, INAM, Universitat Jaume I, Castelló, Spain. Major MEDLINE topics: SARS-CoV-2, Coronavirus 3C Proteases, Lactones, Antiviral Agents. 66 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Spanish Ministerio de Ciencia, Innovación y Universidades / Agencia Estatal de Investigación, Generalitat Valenciana.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

From the arrival of the SARS‐CoV‐2 coronavirus in 2019 and its associated COVID‐19 pandemic, worldwide efforts have been focused on developing a drug to treat patients. The SARS‐CoV‐2 main protease (Mpro) is one of the main targets for drug design due to its key role in the virus replication and its distinguished ability to cleave peptides after a glutamine residue. Inspired by the knowledge of the inhibition mechanism of 20S Proteasome, this work focuses on exploring the inhibition process of SARS‐CoV‐2 M pro with a β‐lactone, as well as the impact of the stereochemistry of this compound on the stability of the enzyme:inhibitor binding formation complex. Based on molecular dynamics simulations with classical and hybrid QM/MM potentials, the free energy landscape of the mechanism of the formation of the covalent complex has been computed. The results show how one of the stereoisomers of the β‐lactone derivative forms a stable reactant non‐covalent complex in the active site of M pro . Analysis of the kinetics and thermodynamics of the inhibition process suggests that this non‐peptidyl compound can be considered a lead compound for future developments of efficient therapeutic compounds to treat patients with COVID‐19.

Subjects

MeSH terms (MEDLINE)

SARS-CoV-2Coronavirus 3C ProteasesLactonesAntiviral AgentsProtease InhibitorsViral Nonstructural ProteinsMolecular Dynamics SimulationStereoisomerismHumansThermodynamicsCatalytic DomainCOVID-19

Author keywords

COVID‐19MDQM/MMSARS‐CoV‐2 Mproinhibitionβ‐lactone

Substances

Coronavirus 3C ProteasesLactonesAntiviral AgentsProtease InhibitorsViral Nonstructural Proteins

Authors and institutions

  • BioComp Group, Institute of Advanced Materials, INAM, Universitat Jaume I, Castelló, Spain.

ORCID profiles: Katarzyna Świderek, Vicent Moliner

Funding

  • Spanish Ministerio de Ciencia, Innovación y Universidades / Agencia Estatal de Investigación
  • Generalitat Valenciana

Cite

APA

Świderek, K., & Moliner, V. (2026). The pivotal role of β‐lactone stereochemistry in the development of SARS ‐ CoV ‐2 M pro inhibitors. Protein Science, 35(7). https://doi.org/10.1002/pro.70680

Vancouver

Świderek K, Moliner V. The pivotal role of β‐lactone stereochemistry in the development of SARS ‐ CoV ‐2 M pro inhibitors. Protein Science. 2026;35(7). doi:10.1002/pro.70680

BibTeX
@article{widerek2026,
  author = {Świderek, Katarzyna and Moliner, Vicent},
  title = {The pivotal role of β‐lactone stereochemistry in the development of SARS ‐ CoV ‐2 M pro inhibitors},
  journal = {Protein Science},
  year = {2026},
  volume = {35},
  number = {7},
  doi = {10.1002/pro.70680}
}
Start for free →